AR and cancer: In PCa, AR inhibition in different cell types, such as epithelial and stromal cells, results in changes in the immune response and inflammation within the TME, ultimately affecting cancer progression and treatment efficacy.[53] These cell types exhibit different androgen and AR requirements during prostate development, which may explain this phenomenon.